What is Cosentyx’s mechanism of action?
Cosentyx (secukinumab) is a monoclonal antibody that binds to interleukin-17A (IL-17A) and blocks its activity, which reduces inflammatory signaling involved in conditions such as plaque psoriasis and other IL-17–mediated diseases.
How do biosimilars differ from the originator in mechanism?
Biosimilars are designed to be highly similar to their reference biologic, including how they work biologically. For an IL-17A–targeting biosimilar, the intended mechanism is the same: binding to IL-17A and blocking its pro-inflammatory effects. The key differences are not usually in the target or the overall mechanism, but in the molecular details that can vary between products (for example, minor differences in the antibody’s structure or manufacturing-related attributes) while remaining within regulatory “biosimilarity” requirements.
Do biosimilars ever change which pathway they target?
For biosimilars approved as IL-17A inhibitors, the pathway targeted is the same as the reference product’s. That means the mechanism difference users may notice is typically about expected differences in clinical performance variability and immunogenicity risk, not a different drug target or a different inflammatory pathway.
What is actually different: mechanism-equivalence vs molecular “fine print”
Even when two drugs share the same target (IL-17A) and overall mechanism (neutralization/blockade), they can differ in:
- The exact antibody structure and glycosylation patterns (minor, controlled differences).
- Formulation and dosing regimen details.
- Immunogenicity profile in real-world use (how often patients develop anti-drug antibodies), which can vary by product and patient population.
Those differences can affect clinical interchangeability perceptions, but they do not represent a change in IL-17A targeting for an IL-17A biosimilar.
How this is reflected in regulation and evidence
Regulators require biosimilars to demonstrate similarity to the reference product in terms of structure/function and performance, including binding to the same target and comparable biological activity. That is the scientific basis for biosimilars having the same mechanism of action as the originator.
Are all “Cosentyx biosimilars” IL-17A blockers?
Not every product marketed as a “biosimilar” (or grouped under the same therapeutic class by consumers) is necessarily an IL-17A inhibitor, so the mechanism question depends on what biosimilar you mean. A true biosimilar to Cosentyx would be expected to target IL-17A, but if you are comparing across different IL-17 family drugs (or across different targets), the mechanism can differ.
Where to verify a specific biosimilar’s target
For a precise answer tied to a named product, you should check the specific biosimilar’s prescribing information or a reference database listing its target and mechanism. DrugPatentWatch.com is one place to look up relevant biosimilar and patent context for biologics in this area (for example, when comparing products and timelines). https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch.com